Synopsis
Synopsis
0
JDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. By 1023
2. By-1023
3. By1023
4. Pantoprazole
5. Protonix
6. Sk And F 96022
7. Sk And F-96022
8. Sk And F96022
9. Skf 96022
10. Skf-96022
11. Skf96022
1. 138786-67-1
2. Pantoloc
3. Protonix
4. Pantecta
5. Zurcal
6. Pantoprazole Sodium Salt
7. Skf96022 Sodium
8. By-1023 Sodium
9. Chebi:50270
10. Sodium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
11. Pantozol Control
12. 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl) Sulfinyl)-1h-benzimidazole Sodium
13. Dsstox_cid_24215
14. Dsstox_rid_80123
15. Dsstox_gsid_44215
16. Sodium 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
17. Sodium 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
18. Cas-138786-67-1
19. Anagastra
20. Inipomp
21. Pantorc
22. Peptazol
23. Ulcotenal
24. Citrel
25. Apton
26. Rifun
27. Pantoprazole Sodium;
28. By1023 (sodium)
29. Pantoprazole Sodium,(s)
30. Skf96022 (sodium)
31. Schembl3543
32. Mls001424073
33. Pantoprazole Sodium Monohydrate
34. Chembl1200408
35. Dtxsid7044215
36. Dz-2352a
37. Hms2051l19
38. Hms3393l19
39. Hms3715d12
40. Act02633
41. Tox21_112996
42. Tox21_302362
43. Mfcd01658543
44. S4538
45. Akos015994677
46. Ccg-100980
47. Ks-1093
48. Nc00230
49. S86p671
50. Sb17369
51. By-1023/sk&f-96022
52. Ncgc00255835-01
53. Smr000469592
54. Ft-0602602
55. Ft-0673508
56. A807440
57. B-8610-23/sk&f-96022-z
58. J-516336
59. B-8510-29
60. Q27122012
61. Sodium 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl] Benzimidazol-1-ide
62. 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole, Sodium Salt
63. 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]benzimidazol-1-ide; Sodium;pantoprazole Sodium
64. Sodium 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
65. Sodium 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}benzimidazol-1-ide
1. Pantozol
2. S-pantoprazole
3. Pantoprazole
Molecular Weight | 405.4 g/mol |
---|---|
Molecular Formula | C16H14F2N3NaO4S |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 7 |
Exact Mass | 405.05707772 g/mol |
Monoisotopic Mass | 405.05707772 g/mol |
Topological Polar Surface Area | 90.8 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 497 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Pantoprazole sodium |
Drug Label | The active ingredient in pantoprazole sodium delayed-release tablets USP is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid... |
Active Ingredient | Pantoprazole sodium |
Dosage Form | Injectable; Tablet, delayed release |
Route | injection; Iv (infusion); Oral |
Strength | eq 20mg base; eq 40mg base/vial; eq 40mg base; 40mg |
Market Status | Tentative Approval; Prescription |
Company | Wockhardt; Mylan Pharms; Hetero Labs Ltd V; Teva Parenteral; Teva; Apotex; Aurobindo Pharma; Torrent Pharms; Sun Pharma Global; Perrigo R And D; Actavis Elizabeth; Macleods Pharms; Jubilant Generics; Kudco Ireland; Ranbaxy Labs; Dr Reddys Labs; Akorn |
2 of 4 | |
---|---|
Drug Name | Protonix iv |
Active Ingredient | Pantoprazole sodium |
Dosage Form | Injectable |
Route | Iv (infusion) |
Strength | eq 40mg base/vial |
Market Status | Prescription |
Company | Wyeth Pharms |
3 of 4 | |
---|---|
Drug Name | Pantoprazole sodium |
Drug Label | The active ingredient in pantoprazole sodium delayed-release tablets USP is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid... |
Active Ingredient | Pantoprazole sodium |
Dosage Form | Injectable; Tablet, delayed release |
Route | injection; Iv (infusion); Oral |
Strength | eq 20mg base; eq 40mg base/vial; eq 40mg base; 40mg |
Market Status | Tentative Approval; Prescription |
Company | Wockhardt; Mylan Pharms; Hetero Labs Ltd V; Teva Parenteral; Teva; Apotex; Aurobindo Pharma; Torrent Pharms; Sun Pharma Global; Perrigo R And D; Actavis Elizabeth; Macleods Pharms; Jubilant Generics; Kudco Ireland; Ranbaxy Labs; Dr Reddys Labs; Akorn |
4 of 4 | |
---|---|
Drug Name | Protonix iv |
Active Ingredient | Pantoprazole sodium |
Dosage Form | Injectable |
Route | Iv (infusion) |
Strength | eq 40mg base/vial |
Market Status | Prescription |
Company | Wyeth Pharms |
Short-term treatment of reflux symptoms (e. g. heartburn, acid regurgitation) in adults.
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
A02BC02
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
12
PharmaCompass offers a list of Pantoprazole Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pantoprazole Sodium manufacturer or Pantoprazole Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pantoprazole Sodium manufacturer or Pantoprazole Sodium supplier.
PharmaCompass also assists you with knowing the Pantoprazole Sodium API Price utilized in the formulation of products. Pantoprazole Sodium API Price is not always fixed or binding as the Pantoprazole Sodium Price is obtained through a variety of data sources. The Pantoprazole Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pantoloc manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pantoloc, including repackagers and relabelers. The FDA regulates Pantoloc manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pantoloc API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pantoloc manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pantoloc supplier is an individual or a company that provides Pantoloc active pharmaceutical ingredient (API) or Pantoloc finished formulations upon request. The Pantoloc suppliers may include Pantoloc API manufacturers, exporters, distributors and traders.
click here to find a list of Pantoloc suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pantoloc DMF (Drug Master File) is a document detailing the whole manufacturing process of Pantoloc active pharmaceutical ingredient (API) in detail. Different forms of Pantoloc DMFs exist exist since differing nations have different regulations, such as Pantoloc USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pantoloc DMF submitted to regulatory agencies in the US is known as a USDMF. Pantoloc USDMF includes data on Pantoloc's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pantoloc USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pantoloc suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pantoloc Drug Master File in Korea (Pantoloc KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pantoloc. The MFDS reviews the Pantoloc KDMF as part of the drug registration process and uses the information provided in the Pantoloc KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pantoloc KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pantoloc API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pantoloc suppliers with KDMF on PharmaCompass.
A Pantoloc CEP of the European Pharmacopoeia monograph is often referred to as a Pantoloc Certificate of Suitability (COS). The purpose of a Pantoloc CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Pantoloc EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Pantoloc to their clients by showing that a Pantoloc CEP has been issued for it. The manufacturer submits a Pantoloc CEP (COS) as part of the market authorization procedure, and it takes on the role of a Pantoloc CEP holder for the record. Additionally, the data presented in the Pantoloc CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Pantoloc DMF.
A Pantoloc CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Pantoloc CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Pantoloc suppliers with CEP (COS) on PharmaCompass.
A Pantoloc written confirmation (Pantoloc WC) is an official document issued by a regulatory agency to a Pantoloc manufacturer, verifying that the manufacturing facility of a Pantoloc active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pantoloc APIs or Pantoloc finished pharmaceutical products to another nation, regulatory agencies frequently require a Pantoloc WC (written confirmation) as part of the regulatory process.
click here to find a list of Pantoloc suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pantoloc as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pantoloc API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pantoloc as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pantoloc and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pantoloc NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pantoloc suppliers with NDC on PharmaCompass.
Pantoloc Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pantoloc GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pantoloc GMP manufacturer or Pantoloc GMP API supplier for your needs.
A Pantoloc CoA (Certificate of Analysis) is a formal document that attests to Pantoloc's compliance with Pantoloc specifications and serves as a tool for batch-level quality control.
Pantoloc CoA mostly includes findings from lab analyses of a specific batch. For each Pantoloc CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pantoloc may be tested according to a variety of international standards, such as European Pharmacopoeia (Pantoloc EP), Pantoloc JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pantoloc USP).